aldosterone synthase inhibitor
AstraZeneca gears up for FDA filing after baxdrostat’s phase 3 hypertension success
AstraZeneca; baxdrostat; hypertension; FDA filing; aldosterone synthase inhibitor; phase 3 trial; regulatory approval
Actionable Insights Powered by AI
AstraZeneca; baxdrostat; hypertension; FDA filing; aldosterone synthase inhibitor; phase 3 trial; regulatory approval